AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (ANGO) management is scheduled to participate in the UBS and Canaccord Genuity investor conferences in November 2026.
The UBS Global Healthcare Conference fireside chat is November 9, from 8:00–8:35 AM ET. The presentation at Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum is November 11, from 1:00–1:25 PM ET. A live webcast of the presentation will be available through the Investors section at www.angiodynamics.com.
AngioDynamics (ANGO) announced publication of DIRECT pancreatic cancer study results and approval of a procedure-reporting code for pancreatic IRE. IRE, or irreversible electroporation, is a non-thermal tissue-ablation technology delivered by NanoKnife. The prospective study at 18 U.S. sites included 137 patients with Stage III pancreatic ductal adenocarcinoma: 99 received systemic therapy plus IRE and 38 received systemic therapy without IRE. Median overall survival from diagnosis was 28 versus 15 months; median progression-free survival was 9 versus 6 months. Grade 3 or higher serious adverse events occurred in 56% versus 71%. The non-randomized findings establish an association, not causation.
The new Category I CPT code covers open pancreatic tumor ablation using IRE, including imaging guidance, and takes effect January 1, 2027. The AMA is expected to publish the final number and descriptor. The code does not determine coverage or guarantee payment.
AngioDynamics (ANGO) announced Humana Medicare Advantage coverage supporting eligible NanoKnife cancer treatments, effective October 1, 2026, under medical necessity criteria.
NanoKnife delivers irreversible electroporation (IRE), which destroys targeted tissue without heat. Humana applies the applicable Medicare Administrative Contractor coverage determination within its jurisdiction and uses LCD L40205 criteria elsewhere. Those criteria cover favorable intermediate-risk prostate cancer, Grade Group 2, and colorectal cancer that has spread to the liver when safe surgical removal or thermal ablation with cancer-free margins is not possible.
Coverage remains subject to prior authorization and member plan terms. Humana has approximately 7 million members. The update follows Category I billing codes for prostate and liver ablation effective January 1, 2026, and Palmetto GBA’s final LCD L40205 effective July 5, 2026.
AngioDynamics (NASDAQ: ANGO) reported fiscal 2027 first-quarter net sales of $80.9 million, up year over year, with narrower losses. For the quarter ended August 31, 2026, sales rose 6.9%; Med Tech grew 13.2% and Med Device grew 1.4%. GAAP gross margin increased to 59.4% from 55.3%, including tariff refunds; without that benefit, it was 57.8%. GAAP net loss narrowed to $7.1 million, or $0.17 per share, from $10.9 million, or $0.26 per share. Adjusted EBITDA rose to $5.0 million from $2.2 million.
Operating cash use was $15.3 million, and cash totaled $34.0 million with no debt. AngioDynamics reiterated fiscal 2027 sales guidance of $336.0 million–$341.0 million and adjusted loss per share of $0.29–$0.24. FDA approval permits the RELIEF feasibility study of NanoKnife for benign prostatic hyperplasia. Eric Honroth will succeed retiring CEO Jim Clemmer on November 2, 2026; Clemmer will remain an executive advisor.
AngioDynamics (NASDAQ: ANGO) appointed Eric Honroth as president, chief executive officer and a board member, effective November 2, 2026. He will succeed Jim Clemmer, who is retiring after ten years as president and CEO. Clemmer will leave the board on November 2 and remain in a consulting role to support the transition.
The appointment follows a board-led search focused on medical technology experience, commercial execution and operational discipline. Honroth brings more than 20 years of medical device and life sciences leadership experience. Most recently, he was Global President, Life Science at Getinge; previously, he led its $1.2 billion North American business. His earlier senior roles included Abbott Vascular, Becton Dickinson, CareFusion and Boston Scientific. AngioDynamics has no outstanding debt.
AngioDynamics (ANGO) and The PERT Consortium selected Jacobi Hospital investigators as ALPHA-PE Research Fund award recipients for pulmonary embolism research.
Dr. Jonathan Alis, Dr. Seth I. Sokol and their team will conduct an independent study of CT pulmonary angiography radiomics, measurable features extracted from lung blood-vessel scans. The study will evaluate whether these features can predict clot biology, success of mechanical clot removal and long-term patient outcomes. The research aims to inform individualized treatment decisions if the imaging features are validated. The fund provides awards ranging from $50,000 to $750,000 over one to three years; these are program-wide terms, not a disclosed amount for Jacobi Hospital.
AngioDynamics (ANGO) will report fiscal 2027 first-quarter results before the market opens on October 8, 2026. Management will discuss the results on a conference call at 8:00 a.m. ET that day. The call will also be webcast through the company’s investor website.
AngioDynamics (NASDAQ: ANGO) announced that its management team will participate in two investor events: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference/b on , and Canaccord Genuity's 46th Annual Growth Conference with a presentation on Tuesday, August 11, 2026 from 3:30–3:55 PM ET. A live webcast of the Canaccord presentation will be available via the Investors section of the company’s website at www.angiodynamics.com.
AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 Q4 pro forma net sales of $86.6 million, up 8.0% year over year, with Med Tech sales up 16.7% to $41.8 million and Med Device sales up 1.1% to $44.8 million. Q4 GAAP gross margin was 54.0%, GAAP loss per share was $0.27, adjusted loss per share $0.07, and adjusted EBITDA $3.3 million.
For fiscal 2026, pro forma net sales grew 9.4% to $320.2 million, with Med Tech up 18.4% to $150.0 million and Med Device up 2.5% to $170.2 million. Full-year GAAP loss per share was $0.88, adjusted loss per share $0.24, and adjusted EBITDA $13.2 million. Gross margin rose to 54.6%, and AngioDynamics ended the year with $53.9 million in cash and no debt. The company highlighted NanoKnife clinical and reimbursement milestones, multiple FDA IDE approvals, and issued fiscal 2027 guidance for net sales of $336–$341 million, Med Tech growth of 12–15%, and adjusted EPS of ($0.29)–($0.24).
AngioDynamics (NASDAQ: ANGO) will release its fiscal 2026 fourth quarter and full-year financial results before market open on Tuesday, July 14, 2026. Management will host a conference call at 8:00 a.m. ET, with live webcast and replay available via the company’s investor website.